Copyright
©The Author(s) 2019.
World J Clin Cases. Aug 26, 2019; 7(16): 2247-2255
Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2247
Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2247
Characteristic | Patients total (n = 20) |
Age (y): Median (range) | 11.5 (8-16) |
Sex, male: | 10 (50) |
Duration (yr) after end of cancer treatment | 4 (1- 9) |
Type of cancer history | |
ALL | 17 (85) |
Hodgkin Lymphoma | 2 (10) |
Non-Hodgkin Lymphoma | 1 (5) |
Weight (kg): Median (range) | 37 (24-64.5) |
Height (cm): Median (range) | 137.5 (114-77) |
BMI (kg/m2): Median (range) | 17.7 (14.56-24.89) |
HCV RNA (log10 IU/mL): Mean (SD) | 6.09 (0.72) |
HCV RNA ≥ 800000 IU/mL | 10 (50) |
Interferon or ribavirin treatment experience | |
Naïve: | 19 (95) |
Non-respondent to IFN Rx | 1 (5) |
METAVIR Score by Fibroscan | |
F1 | 17 (85) |
F2 | 3 (15) |
WBCs (× 10⁹/L): Median (range) | 7.5 (4.1-13.8) |
Hemoglobin (g/dL): Median (range) | 12.05 (10-13.8) |
Platelet Count (× 10⁹/L): Median (range) | 236.5 (66-444) |
AST (IU/L): Mean (SD) | 50.7 (29.4) |
ALT (IU/L): Mean (SD) | 54.3 (40.2) |
S. Total Bilirubin (mg/dL): Median (range) | 0.7 (0.2-1.7) |
S. Creatinine (mg/dL): Median (range) | 0.65 (0.2-0.8) |
Variable [Mean (95%CI)] | At baseline | At wk 4 | At wk 12 | Sig. |
Serum. ALT (IU/L) | 54.3 (35.49– 73.11) | 19.55 (11.02-28.08) | 17.45 (15.11-19.80) | < 0.05 |
Serum AST (IU/L) | 50.7 (36.95-64.45) | 24.05 (16.40-31.70) | 19.95 (17.37-22.53) | < 0.05 |
T. Bilirubin (mg/dl) | 0.66 (0.49-0.82) | 0.53 (0.42-0.64) | 0.55 (0.45-0.65) | No |
S. Creatinine (mg/dl) | 0.6 (0.52-0.68) | 0.59 (0.51-0.66) | 0.61 (0.54-0.68) | No |
WBCs (× 10⁹/L) | 7.27 (6.3-8.2) | 7.62 (6.8-8.5) | 7.3 (6.5-8.1) | No |
Hemoglobin (g/dL) | 12.16 (11.7-12.6) | 11.9 (11.38-12.35) | 11.70 (11.13-12.27) | No |
Platelets (× 10⁹/L) | 243 (203-283) | 235.5 (200-271) | 247.3 (213-281) | No |
- Citation: El-Shabrawi MH, Sherief LM, Yakoot M, Kamal NM, Almalky MA, AbdElgawad MM, Mahfouz AA, Helmy S, Kamal EM, Attia D, El-Khayat HR. Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. World J Clin Cases 2019; 7(16): 2247-2255
- URL: https://www.wjgnet.com/2307-8960/full/v7/i16/2247.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i16.2247